PT  - JOURNAL ARTICLE
AU  - Karen O. Hamilton
AU  - Elizabeth Topp
AU  - Irwan Makagiansar
AU  - Teruna Siahaan
AU  - Mehran Yazdanian
AU  - Kenneth L. Audus
TI  - Multidrug Resistance-Associated Protein-1 Functional Activity in Calu-3 Cells
DP  - 2001 Sep 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 1199--1205
VI  - 298
IP  - 3
4099  - http://jpet.aspetjournals.org/content/298/3/1199.short
4100  - http://jpet.aspetjournals.org/content/298/3/1199.full
SO  - J Pharmacol Exp Ther2001 Sep 01; 298
AB  - The purpose of this work was to determine whether the in vitro bronchiolar epithelial cell model, Calu-3, possesses efflux pump activity by the multidrug resistance-associated protein-1 (MRP1). Reverse transcription-polymerase chain reaction demonstratedMRP1 gene expression in Calu-3 cells. Indirect fluorescence studies showed a basolateral membrane localization of MRP1 compared with P-glycoprotein (Pgp) that was found on the apical side of these cells. An increase in the rate of accumulation of the MRP1 substrate calcein was observed following treatment with the organic anion/MRP1 inhibitor indomethacin, the Pgp inhibitors cyclosporin A (CsA) and vinblastine, as well as conditions of energy depletion. Total calcein efflux was significantly decreased with the MRP1 inhibitors probenecid and indomethacin, while total efflux was unchanged following treatment with CsA. In the latter case, however, intracellular calcein levels postefflux were significantly greater. Probenecid and indomethacin increased calcein net secretion 2.4- and 3.5-fold, respectively. The efflux of etoposide, a known substrate for both Pgp and MRP1, was shown to be mainly Pgp-mediated by using the multidrug-resistant inhibitors quinidine (mixed Pgp/MRP1), CsA (Pgp), and MK571 (MRP1). Together, these data suggest that Calu-3 cells possess MRP1 functional activity that is subordinate to Pgp efflux. We present here kinetic analysis of calcein efflux from Calu-3 cells to support our findings. The American Society for Pharmacology and Experimental Therapeutics